Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 25, 2020 08:00 ET | Source: Castle Creek Biosciences

Castle Creek Biosciences Announces $75 Million Investment to Advance Development of Multiple Gene Therapy Candidates for Rare Diseases

- Leveraging proprietary technology and manufacturing platform to develop transformative gene therapies for multiple rare diseases with high unmet needs - - Pipeline led by Phase 3 gene...
September 12, 2019 17:40 ET | Source: Fibrocell Science Inc.

Castle Creek Pharmaceutical Holdings to Acquire Fibrocell

- Total consideration of $63.3 million, including repayment of debt and other financial instruments - - Acquisition expected to close in the fourth quarter of 2019 - - Further strengthens Castle...
August 14, 2019 16:45 ET | Source: Fibrocell Science Inc.

Fibrocell Reports Second Quarter 2019 Financial Results and Recent Operational Highlights

- Company to Host Conference Call and Webcast on Thursday, August 15 at 8:30 a.m. EDT - EXTON, Pa., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy...
May 30, 2019 08:00 ET | Source: Fibrocell Science Inc.

Fibrocell to Present at BIO International Convention 2019

EXTON, Pa., May 30, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
May 29, 2019 08:00 ET | Source: Fibrocell Science Inc.

Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB

EXTON, Pa., May 29, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
May 15, 2019 07:30 ET | Source: Fibrocell Science Inc.

Fibrocell Reports First Quarter 2019 Financial Results and Recent Operational Highlights

EXTON, Pa., May 15, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
May 09, 2019 08:00 ET | Source: Fibrocell Science Inc.

Fibrocell to Host Conference Call and Webcast on Wednesday, May 15, 2019 to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights

EXTON, Pa., May 09, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
April 15, 2019 06:30 ET | Source: Fibrocell Science Inc.

Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy

- Fibrocell to receive up to $135 million, including up to $30 million in upfront, near-term and development payments and a 30% gross profit share - - Fibrocell retains rights to the eligible Rare...
April 03, 2019 08:00 ET | Source: Fibrocell Science Inc.

Fibrocell Announces Board Member Christine St.Clare Honored by National Association of Corporate Directors

- Annual NACD Directorship 100 List Recognizes the Most Influential Corporate Governance Experts - EXTON, Pa., April 03, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene...
March 27, 2019 07:30 ET | Source: Fibrocell Science Inc.

Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007

- Phase 3 clinical trial, named DEFI-RDEB, is expected to commence in the second quarter of 2019 - - Additional data from Phase 1/2 clinical trial demonstrates FCX-007 continues to be well...